Clinical trials: PET-CT
Prostate Cancer
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer [18F]FTT to evaluate PARP-1 activity in known or…
- Trial name
- NCT03334500
- Testing
- [18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Atherosclerosis, Cardiovascular Diseases
Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease
The INTENSITY-HIGH study aims to answer if there are any limits to LDL reduction in relation to benefiting vascular health, exploring the mechanisms by which secondary prevention in patients with established heart disease may…
- Trial name
- INTENSITY-HIGH (NCT03355027)
- Testing
- Alirocumab 150 MG/ML, Ezetimibe 10Mg Tablet, Atorvastatin 40Mg Tablet
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Recurrent Breast Cancer, Stage IV Breast Cancer
Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer
The standard diagnostic workup for recurrent or metastatic breast cancer includes biopsy and determination of tumor estrogen status according to National Comprehensive Cancer Network and European Society for Medical Oncology.
- Trial name
- NCT01986569
- Testing
- [18F]fluoroestradiol (FES)
- Where
- South Korea
- Volunteers
- 93 people
- Sponsor
- Asan Medical Center
Lung Cancer
A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer
The purpose of this study is to determine if the images of the primary lesions of lung cancer and any metastatic lesions seen from the investigational SPECT/CT 99mTC-EC-DG scans are the same as the PET/CT 18F-FDG scans.
- Trial name
- NCT01394679
- Testing
- (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose), 18 F FDG followed by PET/CT imaging
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Cell>Point LLC
Prostatic Neoplasms, Prostate Cancer
18F-DCFBC PET/CT in Prostate Cancer
Background: Prostate cancer is the second leading cause of cancer deaths in American men. A chemical called a radiotracer helps doctors get images of this type of cancer.
- Trial name
- NCT02190279
- Testing
- 18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Radiotherapy
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
This is a prospective, single-center, phase II, randomized, window-of-opportunity trial initiated by researchers. The research hypothesis is that metformin can improve the level of hypoxia in locally advanced cervical cancer and…
- Conditions
- Cervical Cancer, Radiotherapy, Metformin, Hypoxia
- Trial name
- NCT06353061
- Testing
- Metformin, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available, If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT
FDG PET-CT in Advanced Breast Cancer
This study is a prospective cohort study comparing metabolic response evaluation by F-18 FDG PET-CT versus conventional imaging for outcome stratification in patients with advanced breast cancer receiving first-line systemic…
- Trial name
- PET-000 (NCT07173868)
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Prostate Cancer
68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
To evaluate the dosimetry, safety and the detection rate of 68Ga-THP-PSMA PET/CT for identifying the site of prostate cancer metastasis and relapse.
- Trial name
- NCT04158817
- Testing
- 68Ga-Labeled PSMA, Non-labeled PSMA
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Cancer, Malignant Neoplasm
A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors
The investigators designed and synthesized a novel fibroblast activation protein (FAP) ligand (DOTA-GPFAPI-04) by assembling three functional moieties: a quinoline-based FAP inhibitor for specifically targeting FAP, a FAP…
- Conditions
- Cancer, Malignant Neoplasm, Tumors, Metastatic Cancer
- Trial name
- 68Ga-GPFAPI (NCT06186427)
- Testing
- 68Ga-DOTA-GPFAPI-04 PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Lymphoma, Bone Marrow Neoplasm
PET Guided Bone Marrow Biopsy vs Trephine Bone Marrow Biopsy
Newly diagnosed lymphoma patients were recruited for FDG PET/CT and PET/CT guided bone marrow biopsy. All the patients also underwent routine bone marrow sampling from the posterior superior iliac spine.
- Trial name
- NCT05251168
- Testing
- PET Guided Bone Marrow Biopsy, Trephine Bone Marrow Biopsy
- Where
- India
- Volunteers
- 180 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Obesity, Metabolic Syndrome
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly…
- Conditions
- Obesity, Metabolic Syndrome, Brown Adipose Tissue
- Trial name
- BAT-Sema (NCT07621640)
- Testing
- Semaglutide (Wegovy®), ¹⁸FDG-PET/CT with cold stimulation, Liver MRI (PDFF + MRE)
- Where
- 2 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Hallym University
Lymphoma
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
Background: Positron emission tomography (PET) uses radioactive substances called radiotracers to locate areas of cancer in the body.
- Trial name
- NCT00775268
- Testing
- Biopsy, fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography, [3'-deoxy-3'-[F-18] fluorothymidine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Presence of COVID-19 Compatible CT Abnormalities
CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients
CT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i)…
- Trial name
- NCT04512118
- Testing
- PET-CT of 18F-FDG
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Central Hospital, Nancy, France
Carcinoid Cancer, Neuroendocrine Tumors
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
- Conditions
- Carcinoid Cancer, Neuroendocrine Tumors, Medullary Thyroid Cancer, Cancers Expressing Somatostatin Receptors
- Trial name
- NCT02174679
- Testing
- 68Ga DOTATATE
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, PET/CT
Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [18F]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of…
- Trial name
- NCT06462508
- Testing
- [18F]F-PSMA-N5, [68Ga]Ga-PSMA-11
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Thyroid Gland
Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study
The purpose of the study is to investigate the contribution of PET-CT with F18-choline in the diagnosis of thyroid nodule with indeterminate cytology in order to guide the best indication of surgical resection.
- Trial name
- CHOCOLATE (NCT02784223)
- Testing
- Radiation : PET-CT with F18-choline examination
- Where
- France
- Volunteers
- 107 people
- Sponsor
- Centre Francois Baclesse
Radiation Therapy, Metastatic Renal Cancer
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and…
- Conditions
- Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
- Trial name
- COSTAR-002 (NCT07540260)
- Testing
- PETCT-guided radiation therapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
Oral Cancer, Oropharyngeal Cancer
uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
uPAR PET/CT for Staging Advanced and Localised oral and oropharyngeal cancer
- Conditions
- Oral Cancer, Oropharyngeal Cancer, Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT02960724
- Testing
- 68Ga-NOTA-AE105 PET/CT
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Primary Malignant Liver Neoplasm
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors
This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors .
- Trial name
- NCT03109262
- Testing
- Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Stanford University
Gynecologic Cancer, Radiotherapy Side Effect
Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)
This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy…
- Conditions
- Gynecologic Cancer, Radiotherapy Side Effect, Radiotherapy; Complications, Survivorship
- Trial name
- GYN-ART (NCT06306170)
- Testing
- Image Guided Radiotherapy
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS San Raffaele
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.